Remove 2003 Remove Pharma Companies Remove Pharmaceuticals Remove Trials
article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

The campus is home to GSK, the Cell and Gene Therapy Manufacturing Catapult, LifeArc and Cytiva, alongside a growing cluster of start-up companies which together have raised £2.9 Next, Saleko highligts how Northumberland and the North East of the UK are recognised for pharmaceutical manufacturing prowess. billion in funding.

Drugs 189
article thumbnail

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects

The Pharma Data

Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. The Ampligen EAP protocol is authorized to enroll up to 100 active trial participants, 20 of whom may be Long Haulers. development pipeline for ME/CFS. All study subjects will receive the same Ampligen treatments. See: PLOS ONE ).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Decentralised identities: Blockchain based informed consent

Drug Discovery World

Industry experts explain how blockchain can fundamentally enhance clinical trials. Obtaining consent from patients or healthy volunteers is a fundamental requirement for enrolling participants on to clinical trials. Along the study, patients are usually reconsented multiple times following a change in the trial protocol, eg.

article thumbnail

Decentralised identities: Blockchain based informed consent

Drug Discovery World

Industry experts explain how blockchain can fundamentally enhance clinical trials. Obtaining consent from patients or healthy volunteers is a fundamental requirement for enrolling participants on to clinical trials. Along the study, patients are usually reconsented multiple times following a change in the trial protocol, eg.